首页> 外文期刊>Multiple sclerosis: clinical and laboratory research >The (AAT)n repeat of the cannabinoid CB1 receptor gene influences disease progression in relapsing multiple sclerosis.
【24h】

The (AAT)n repeat of the cannabinoid CB1 receptor gene influences disease progression in relapsing multiple sclerosis.

机译:大麻素CB1受体基因的(AAT)n重复影响复发性多发性硬化症的疾病进展。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Genetic and pharmacological inactivation of cannabinoid CB(1) receptors (CB(1)Rs) exacerbates disease course in experimental autoimmune encephalomyelitis, suggesting that CB(1)Rs might play a role in the neurodegenerative damage associated with multiple sclerosis (MS). OBJECTIVES: To see whether CNR1 gene polymorphism could influence disease progression in relapsing-remitting MS. METHODS: The genotype of 350 patients for the number of AAT repeats was characterized and correlation studies were performed with measures of disease severity and progression. RESULTS: MS patients with the homozygous genotype for long AAT repeats in the CNR1 gene had more severe disease and higher risk of progression. These subjects had significantly higher scores on both the progression index and the MS severity scale. Furthermore, the percentage of patients with MS functional composite score progression or Bayesian Risk Estimate for MS (BREMS) score >/= 2 (considered at very high risk of secondary progression) was significantly higher in the AAT long group than in the short group, while the frequency of patients with BREMS score
机译:背景:大麻素CB(1)受体(CB(1)Rs)的遗传和药理失活加剧了实验性自身免疫性脑脊髓炎的疾病进程,表明CB(1)Rs可能在与多发性硬化症(MS)相关的神经退行性损伤中起作用。目的:观察CNR1基因多态性是否会影响复发缓解型MS的疾病进展。方法:对350例AAT重复次数的基因型进行了表征,并通过疾病严重程度和进展进行了相关研究。结果:在CNR1基因中具有长AAT重复的纯合基因型的MS患者病情更严重,进展风险更高。这些受试者在进展指数和MS严重程度量表上得分均明显较高。此外,在AAT长组中,具有MS功能综合评分进展或MS的贝叶斯风险估计(BREMS)评分> / = 2(被认为具有较高的继发进展风险)的患者百分比显着高于短组,两组BREMS得分

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号